Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) shares rose 1.04% to $768.58 on Wednesday, marking its second consecutive day of gains. However, the stock underperformed compared to competitors like Amgen, which surged 4.57%. Trading volume remained significantly below the 50-day average. Despite the daily increase, Regeneron closed 6.40% below its 52-week high reached in January.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) rose 1.04% to $768.58 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.49% to 54,349.12 and the S&P 500 Index falling 0.17% to 7,723.55.
This was the stock's second consecutive day of gains.
Regeneron Pharmaceuticals Inc. closed 6.40% below its 52-week high of $821.11, which the company reached on January 9th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc. (AMGN) rose 4.57% to $407.83, Moderna Inc. (MRNA) fell 1.29% to $56.26, and Gilead Sciences Inc. (GILD) fell 2.58% to $131.76.
Trading volume (529,809) remained 465,545 below its 50-day average volume of 995,354.
Data source: Dow Jones Market Data, FactSet. Data compiled August 5, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-05-26 1645ET